Acute coronary syndromes
KEYWORDS: people, coronary, acute, pci, risk, acute coronary, therapy, recommendations, committee, evidence, angina, unstable, nstemi, unstable angina, offer

(TA335, 2015). 1.4.5 Rivaroxaban plus aspirin is recommended as an option in NICE technology appraisal guidance for preventing atherothrombotic events in some people with coronary artery disease who are at high risk of ischaemic events, taking bleeding risk into account. For full details, see the guidance on rivaroxaban (TA607, 2019). ACE inhibitors 1.4.6 Offer people who present acutely with an MI, an ACE inhibitor as soon as they are haemodynamically stable. Continue the ACE inhibitor indefinitely. [2013] 1.4.7 Titrate the ACE inhibitor dose upwards at short intervals (for example, every 12 to 24 hours) before the person leaves hospital until the maximum tolerated or target dose is reached. If it is not possible to complete the titration during this time, it should be completed within 4 to 6 weeks of hospital discharge. [2013] 1.4.8 Do not offer combined treatment with an ACE inhibitor and an angiotensin II receptor blocker (ARB) to people after an MI, unless there are other reasons to use this combination. [2013] 1.4.9 After an MI, offer people who are intolerant to ACE inhibitors, an ARB instead of an ACE inhibitor. [2013] 1.4.10 Renal function, serum electrolytes and blood pressure should be measured before starting an ACE
